undefined undefined
NaN.000
NaN.00%
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs...
03-12 21:00
Manufacturing Process for Phase 3 and Commercial Production Being Developed for...
03-06 10:00
Geovax Labs (NASDAQ:GOVX) reported its Q4 earnings results on Thursday, Februar...
03-01 05:10
Geovax Labs (NASDAQ:GOVX) reported quarterly losses of $(3.940) per share which missed the analyst consensus estimate of $(2.780) by 41.73 percent.
03-01 05:08
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
02-29 18:15
Geovax Labs (NASDAQ:GOVX) is set to give its latest quarterly earnings report o...
02-29 03:02
Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand f...
02-13 22:00
80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA,...
2023-12-01 05:30
Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 VariantsGeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today
2023-11-14 22:21
HC Wainwright & Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:GOVX) with a Buy and maintains $8 price target.
2023-11-13 20:48